Gilead Sciences Inc — Drug Safety Profile

Average Safety Score: 79/100 · Elevated

13 drugs in portfolio

About Gilead Sciences Inc

Gilead Sciences Inc is a pharmaceutical manufacturer with 13 drugs tracked in the FDA Adverse Event Reporting System (FAERS) database. Across its drug portfolio, Gilead Sciences Inc has an average safety score of 79 out of 100, which indicates a relatively favorable safety profile based on the volume and severity of reported adverse events. This page provides a comprehensive safety overview of all drugs manufactured by Gilead Sciences Inc, including individual drug safety scores and links to detailed adverse event analyses.

The safety data presented here is derived from FDA adverse event reports submitted by healthcare professionals, patients, and manufacturers. These reports are voluntarily submitted and do not by themselves prove that a drug caused an adverse event. However, patterns in reporting volume and severity across a manufacturer's portfolio can provide useful context when evaluating medication safety.

Drugs by Gilead Sciences Inc

Below is the full list of drugs manufactured by Gilead Sciences Inc that appear in the FDA adverse event database, along with their individual safety scores. Click on any drug name to view its complete side effect profile, adverse reaction breakdown, and AI-powered safety analysis.

How We Calculate Manufacturer Safety Scores

The average safety score for Gilead Sciences Inc is computed by aggregating the individual safety scores of each drug in their portfolio. Each drug's safety score is based on the total number of FDA adverse event reports, the severity of reported outcomes including hospitalizations and deaths, and the proportion of serious versus non-serious events. A higher score indicates fewer and less severe adverse events relative to the drug's usage volume.

Disclaimer: Based on FDA adverse event reports. Not medical advice. Adverse event reports do not prove causation. Always consult your healthcare provider before making medication decisions.